Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- RAC
- Ann: Race releases complete cardio-protection data & video
Ann: Race releases complete cardio-protection data & video, page-228
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.74 |
Change
0.035(2.06%) |
Mkt cap ! $290.5M |
Open | High | Low | Value | Volume |
$1.76 | $1.79 | $1.70 | $255.4K | 146.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 18 | $1.73 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.74 | 609 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 18 | 1.730 |
1 | 4373 | 1.725 |
1 | 2499 | 1.715 |
1 | 4798 | 1.710 |
1 | 321 | 1.705 |
Price($) | Vol. | No. |
---|---|---|
1.735 | 1859 | 1 |
1.750 | 400 | 1 |
1.765 | 509 | 1 |
1.790 | 5825 | 2 |
1.800 | 13808 | 4 |
Last trade - 14.38pm 02/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |